next-generation B-Raf inhibitors (Deciphera)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug Namenext-generation B-Raf inhibitors (Deciphera)

Drug Alias NameDP-2473DP-3346DP-2514

ClassificationSmall molecules

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsSerine/threonine-protein kinase B-raf inhibitorsVascular endothelial growth factor receptor 2 antagonists +[5]

TargetsPlatelet-derived growth factor receptorVascular endothelial growth factor receptor 2Serine/threonine-protein kinase B-raf +[4]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesDeciphera Pharmaceuticals Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDeciphera Pharmaceuticals Llc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A